ReviewOncogene2001
Autocrine and paracrine signaling through neuropeptide receptors in human cancer.
Review in Oncogene, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
71 citing papers in PubMed, 200 citations in OpenAlex.
- Collagen gel droplet-embedded culture drug sensitivity test for adjuvant chemotherapy after complete resection of non-small-cell lung cancer.Surgery today · 2018Trial
- Expression and Function of Vasopressin Receptors in the HT-29 Cell Line.Current molecular medicine · 2026Article
- Strategies and applications of synthetic cell communication.Nature chemical biology · 2025Review
- Research Progress of GPR137 in Malignant Tumors: A Review.OncoTargets and therapy · 2025Review
- Article
- Mechanisms of extracellular vesicle uptake and implications for the design of cancer therapeutics.Journal of extracellular biology · 2024Review
- Collective directional migration drives the formation of heteroclonal cancer cell clusters.Molecular oncology · 2023Article
- Systematic molecular analysis of the human secretome and membrane proteome in gastrointestinal adenocarcinomas.Journal of cellular and molecular medicine · 2022Article
- The Role of Neuropeptide-Stimulated cAMP-EPACs Signalling in Cancer Cells.Molecules (Basel, Switzerland) · 2022Review
- dDAVP Downregulates the AQP3-Mediated Glycerol TransportFrontiers in cell and developmental biology · 2022Article
- Towards principled design of cancer nanomedicine to accelerate clinical translation.Materials today. Bio · 2022Review
- Signaling via the FLP-14/FRPR-19 neuropeptide pathway sustains nociceptive response to repeated noxious stimuli in C. elegans.PLoS genetics · 2021Article
- Review
- Small-cell lung cancer.Nature reviews. Disease primers · 2021Review
- Comprehensive Analysis of Survival-Related lncRNAs, miRNAs, and mRNAs Forming a Competing Endogenous RNA Network in Gastric Cancer.Frontiers in genetics · 2021Article
- Identification of Human Secretome and Membrane Proteome-Based Cancer Biomarkers Utilizing Bioinformatics.The Journal of membrane biology · 2020Article
- The Neuropeptide System and Colorectal Cancer Liver Metastases: Mechanisms and Management.International journal of molecular sciences · 2020Review
- Article
- KRAS, YAP, and obesity in pancreatic cancer: A signaling network with multiple loops.Seminars in cancer biology · 2019Review
- Utilizing Peptide Ligand GPCRs to Image and Treat Pancreatic Cancer.Biomedicines · 2018Review
11 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Autocrine and paracrine signaling leading to stimulation of tumor cell growth is a common theme in human cancers. In addition to polypeptide growth factors such as EGF family members which signal through receptor tyrosine kinases, accumulating evidence supports the autocrine and paracrine involvement of specific neuropeptides with defined physiologic actions as neurotransmitters and gut hormones in lung, gastric, colorectal, pancreatic and prostatic cancers. These neuropeptides, including gastrin-releasing peptide, neuromedin B, neurotensin, gastrin, cholecystokinin and arginine vasopressin bind seven transmembrane-spanning receptors that couple to heterotrimeric G proteins. Studies with human small cell lung cancer (SCLC) cells support a requirement for balanced signaling through G(q) and G(12/13) proteins leading to intracellular Ca2+ mobilization, PKC activation and regulation of the ERK and JNK MAP kinase pathways. While specific neuropeptide antagonists offer promise for interrupting the single neuropeptide autocrine systems operating in pancreatic and prostatic cancers, SCLC is exemplified by multiple, redundant neuropeptide autocrine systems such that tumor growth cannot be inhibited with a single specific antagonist. However, a novel class of neuropeptide derivatives based on the substance P sequence have been defined that exhibit broad specificity for neuropeptide receptors and induce apoptosis in SCLC by functioning as biased agonists that stimulate discordant signal transduction. Thus, interruption of autocrine and paracrine neuropeptide signaling with specific antagonists or broad-spectrum biased agonists offer promising new therapeutic approaches to the treatment of human cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.